This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langer, C. J. Articles by Ettinger, D. S. Search for Related Content PubMed PubMed Citation Articles by Langer, C. J. Articles by Ettinger, D. S.

The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy

^a Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA; ^b Johns Hopkins Oncology, Baltimore, Maryland, USA

Correspondence: Corey J. Langer, M.D., Department of Medical Oncology, Fox Chase Cancer Center, Central and Shelmire Avenue, Philadelphia, Pennsylvania 19111, USA. Telephone: 215-728-2985; Fax: 215-728-3639; e-mail: c_langer{at}oberon.fccc.edu or dogbusby{at}aol.com

Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20% of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents—in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors—have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.

Key Words. NSCLC (Non-small cell lung cancer) • Paclitaxel • Chemotherapy • Metastatic disease • Paclitaxel-carboplatin combination

This article has been cited by other articles:

				M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, and J. Belinson Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center J. Clin. Oncol., January 5, 2000; 18(1): 102 - 102. [Abstract] [Full Text] [PDF]